包裹阿霉素的VEGF-脂质体体外靶向杀伤人胃癌血管内皮细胞

VEGF-Liposomes Encapsulated Adriamycin in the Targeting of Human Gastric Tumor-Derived Vascular Endothelial Cells in Vitro

目的:利用包裹阿霉素的血管内皮生长因子(VEGF)-脂质体于体外观察其对肿瘤血管内皮细胞的杀伤作用。方法:利用体外细胞毒实验(MTT)方法,检测VEGF-阿霉素脂质体对肿瘤血管内皮细胞的杀伤作用。结果:48h细胞毒试验连有VEGF的阿霉素脂质体对肿瘤血管内皮细胞的杀伤作用优于无VEGF的阿霉素脂质体(P<0.05),而对非靶细胞(人血管平滑肌细胞)的杀伤作用两者相近。0.5 h预处理试验表明:缩短药物与细胞接触时间后,VEGF-阿霉素脂质体仍保持较强的杀伤肿瘤血管内皮细胞的作用。结论:VEGF修饰的阿霉素脂质体对肿瘤血管内皮细胞的杀伤作用较无VEGF组和非靶细胞组强,可望成为一种有效的抗肿瘤物质。

Objective: To evaluate the targeting ability and cytotoxicity of adriamycin (ADM) liposomes conjugated with VECF in vitro. Methods: MTT assay was used to detect the cytotoxicity of adriamycin liposomes conjugated with VEGF against tumor-derived vascular endothelial cells. Results: Results of 48 h cytotoxicity assay with MTT method showed that specific cytotoxicity of VEGF- liposomes group to endothelial cells were 28.6 fold more effective than the control non-VEGF-lipoaomes group, but with very similar cytotoxicity to non-targeted smooth muscle cells.0.5 h pretreatrnent assay demonstrated that cytotoxicity of free ADM on endothelial cells decreased remarkably(IC50 = 76.7 μmol/L),but adriamycin liposomes conjugated with VEGF remain higher activity(IC50 = 6.12μmol/L) than control non-VEGF-liposomes group (IC50> 100 μmol/L) after reducing the contact time(to 0.5 h)between drugs and cells. Conclusion: Results indicated that cytotoxicity of adriamycin liposomes conjugated with VEGF on vascular endothelial cells was higher than on non-targeted smooth muscle cells and higher than non- VEGF modified ADM liposomes and free ADM group were observed. This formulation of adriamycin liposomes conjugated with VEGF might be an effective anti-rumor agent.